## Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation: Correction

In "Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation" from the American College of Obstetricians and Gynecologists, ${ }^{1}$ there is an error on page e211 in the sentence on line 13 of the "Ultrasonography" section of the document. The text incorrectly reads, " $2{ }^{\circ} \mathrm{C}\left(35.6^{\circ} \mathrm{F}\right)$ " and should instead read, " $2{ }^{\circ} \mathrm{C}$ $\left(3.6^{\circ} \mathrm{F}\right)$." The full, corrected sentence is as follows: "At this intensity, the theoretical increase in temperature elevation for the fetus may be as high as $2^{\circ} \mathrm{C}\left(3.6^{\circ} \mathrm{F}\right)(2,3) . "$

## REFERENCE

1. Guidelines for diagnostic imaging during pregnancy and lactation. Committee Opinion No. 723. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;130:e210-6.

DOI: 10.1097/AOG.0000000000002858

## Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice: Correction

In "Committee Opinion No. 738: Aromatase Inhibitors in Gynecologic Practice" from the American College of Obstetricians and Gynecologists, ${ }_{1}^{1}$ there is an error on page e 196, second column, first paragraph. In the first full sentence, the phrase "letrozole was more effective than clomiphene citrate with a higher live birth rate $(27.5 \%$ versus $10.1 \%$. $P=.007)$ " is incorrect and should instead read, "letrozole was more effective than clomiphene citrate with a higher live birth rate $(27.5 \%$ versus $19.1 \%$, $P=.007)$. " The full, corrected sentence is as follows: "However, in a more recent randomized controlled trial, letrozole was more effective than clomiphene citrate with a higher live birth rate $(27.5 \%$ versus $19.1 \%, P=.007)$, and cumulative ovulation rate $(61.7 \%$ versus $48.3 \%$, $P<.001$ ) (29)."

## Reference

Aromatase inhibitors in gynecologic practice. ACOG Committee Opinion No. 738. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;131:e194-9.

DOI: 10.1097/AOG.0000000000002879

## Effects of the Affordable Care Act on Young Women With Gynecologic Cancers: Correction

There is an error in a range of years reported in the abstract of the article, "Effects of the Affordable Care Act on Young Women With Gynecologic Cancers: Correction."' In the abstract, Methods section, the incorrect sentence is, "We used the National Cancer Database with the 2004-2009 surveys as the pre-ACA years and the 2011-2014 surveys as the post-ACA years." The correct sentence is, "We used the National Cancer Database with the 2006-2009 surveys as the pre-ACA years and the 2011-2014 surveys as the post-ACA years."

## Reference

Smith AJB, Fader AN. Effects of the Affordable Care Act on young women with gynecologic cancers. Obstet Gynecol 2018;131:966-76.

DOI: 10.1097/AOG.0000000000002880

## A 17 $\beta$-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial: Correction

The key for Figure 3B is incorrect in the article, "A 17b-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial." A corrected version of Figure 3 is printed below.

## REFERENCE

1. Lobo RA, Archer DF, Kagan R, Kaunitz AM, Constantine GD, Pickar JH, et al. A 17 $\beta$-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2018;132:161-70.

DOI: 10.1097/AOG.0000000000002859

